Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RET inhibitor SY-5007

An orally bioavailable inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, RET inhibitor SY-5007 selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	SY 5007 SY-5007 SY5007

RET inhibitor SY-5007

Search NCI's Drug Dictionary